[Combined use of radiosensitizing and protective agents in experimental radiotherapy].
The appropriateness of the combined use of electron acceptor radiosensitizers: 4-nitroimidazole and metronidazole, and sulfhydryl protectors WR-2721 (gammaphos) and cysteamine was shown on the Chinese hamster cells V-79 and transplantable mouse tumors. The administration of the sensitizer 30-60 min and the protector 15-20 min before the irradiation of solid tumors weakens radiation reactions of the skin (metronidazole plus gammaphos) without weakening the effect of radiosensitization on transplantable animal tumors (metronidazole plus gammaphos or 4-nitroimidazole plus WR-2721).
D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D006224:Cricetinae; D003412:Cricetulus; D004359:Drug Therapy, Combination; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D011833:Radiation Injuries, Experimental / Q000209:etiology / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011879:Radiotherapy Dosage
D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents
Sochetannoe primenenie radiosensibilizatorov i protektorov pri éksperimental'noĭ luchevoĭ terapii.